Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.

Cano, Antonio; Nappi, Rossella E; Santoro, Nanette; Stute, Petra; Blogg, Martin; English, Marci L; Morga, Antonia; Scrine, Ludmila; Siddiqui, Emad; Ottery, Faith D (2024). Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG : an international journal of obstetrics and gynaecology, 131(9), pp. 1296-1305. Wiley 10.1111/1471-0528.17773

Preview

Text BJOG_-_2024_-_Cano_-_Fezolinetant_impact_on_health_related_quality_of_life_for_vasomotor_symptoms_due_to_the_menopause_.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview

OBJECTIVE

To assess the effect of fezolinetant treatment on health-related quality of life using pooled data from SKYLIGHT 1 and 2 studies.

DESIGN

Prespecified pooled analysis.

SETTING

USA, Canada, Europe; 2019-2021.

POPULATION

1022 women aged ≥40 to ≤65 years with moderate-to-severe vasomotor symptoms (VMS; minimum average seven hot flushes/day), seeking treatment for VMS.

METHODS

Women were randomised to 12-week double-blind treatment with once-daily placebo or fezolinetant 30 or 45 mg. Completers entered a 40-week, active extension (those receiving fezolinetant continued that dose; those receiving placebo re-randomised to fezolinetant received 30 or 45 mg).

MAIN OUTCOME MEASURES

Mean changes from baseline to weeks 4 and 12 on Menopause-Specific Quality of Life (MENQoL) total and domain scores, Work Productivity and Activity Impairment questionnaire specific to VMS (WPAI-VMS) domain scores, Patient Global Impression of Change in VMS (PGI-C VMS); percentages achieving PGI-C VMS of 'much better' (PGI-C VMS responders). Mean reduction was estimated using mixed model repeated measures analysis of covariance.

RESULTS

Fezolinetant 45 mg mean reduction over placebo in MENQoL total score was -0.57 (95% confidence interval [CI] -0.75 to -0.39) at week 4 and -0.47 (95% CI -0.66 to -0.28) at week 12. Reductions were similar for 30 mg. MENQoL domain scores were also reduced and WPAI-VMS scores improved. Twice as many women receiving fezolinetant reported VMS were 'much better' than placebo based on PGI-C VMS assessment.

CONCLUSIONS

Fezolinetant treatment was associated with improvement in overall QoL, measured by MENQoL, and work productivity, measured by WPAI-VMS. A high proportion receiving fezolinetant felt VMS were 'much better' based on PGI-C VMS responder analysis.

Interest & Impact

Downloads

91 since deposited on 07 Feb 2024
91 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item